Ontario’s move away from brand name Methadose has sparked concerns the switch could negatively impact those who rely on the drug, prompting calls for more buy-in from methadone users ahead of these changes.
The current state of our health system means viable alternative approaches are needed. Private plans are not perfect, and neither are provincial plans. But both payer groups need to better protect Canadians from ruinous drug costs.
As a Canadian with Type 1 diabetes I’m dismayed by the way pharmaceutical companies have driven up insulin prices, created a global oligarchy and increased the burden on those who need this life-giving medicine.
We are seeing an increase in dangerous microbes becoming resistant to antimicrobial drugs. To counter this threat, we must reduce our use of the drugs and explore innovative treatments that could one day replace them.
Health Canada has a controversial plan for regulating new, complex health tech. Instead of the old vetting and approval process, a company and the agency would decide the standards as they go. Does this enable innovation or put patient safety at risk?
For many Canadians, important pharmaceuticals are too expensive. But initiatives by the Trudeau government and a federal regulator to combat this problem won't help Canadians access new, life-saving, but costly medicines. Just the opposite.
Hydroxychloroquine was touted as a miracle cure for COVID-19 by Trump, then finished 2020 plagued with concerns about adverse cardiac events. But HCQ is a remarkable medication with a fascinating history.
Please use the invisible republishing code below on the page where you republish this article.
Please give credit to Healthy Debate and include a link back to our home page or the article URL . Our preference is a credit at the top of the article and that you include our logo (available by clicking the link below).
Please read the full set of instructions for republication here.